TECLens Secures Funding for qCXL

TECLens raises $10 Million to advance its non-invasive vision correction platform

To support clinical development of the quantitative corneal cross-linking (qCXL) platform for non-invasive refractive vision correction.

Funding Details: TECLens closed a $10 million Series A2 extension financing, with participation from existing investors including Johnson & Johnson Innovation.
Clinical Development: Proceeds will support the expansion of the first-in-human proof-of-concept program, generation of clinical data, development of the next-generation system, and preparation for investigational device exemption submission.
Technology Overview: The CXLens System reshapes the cornea using personalized patterns of ultraviolet light without cutting or removing corneal tissue, creating molecular bonds to produce controlled changes in corneal shape.

The ongoing proof-of-concept study is evaluating qCXL in patients with refractive errors, focusing on presbyopia.
The financing round was expanded due to additional investor interest.